Abstract
Ovarian cancer is the fifth most common form of cancer in women in the United States, accounting for 4% of the total number of cancer cases and 25% of those cases occur in the female genital tract. Because of its low cure rate, it is responsible for 5% of all cancer deaths in women. It was estimated that 12,180 deaths would be caused by ovarian cancer in the year 2006 (Jemal et al. 2006).
Epithelial ovarian tumors are classified as benign, low malignant potential (LMP), or malignant (Serov and Scully 1973) and further distinguished by differences in the histologic type of cell. Benign ovarian tumors are lined by a single, or minimally stratified layer of cells, which are columnar and often ciliated in serous tumors or contain abundant apical cytoplasmic mucin in mucinous tumors. LMP tumors or borderline tumors (BOT) are characterized by atypical epitheliums with cellular proliferation and pleomorphism, but without stromal invasion. Malignant epithelium demonstrates marked atypia, increased mitotic activity, and stromal invasion.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abeler, V., Kjostad, K. and Berle, E. (1992) Carcinoma of the endometrium in Norway: a histopathological. and prognostic survey. of a total population. Int. J. Gynecol. Cancer 2:9–22
Allikmets, R., Gerrard, B., Hutchinson, A. and Dean, M. (1996) Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum. Mol. Genet. 5:1649–1655
Behbakht, K., Randall. T.C., Benjamin, I., Morgan M.A., King, S., Rubin, S.C. (1998) Clinical characteristics of clear cell carcinoma of the ovary. Gynecol. Oncol. 70:255–258
Bukowski, R.M. (1997) Natural history. and therapy of. metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80:1198–1220
Goff, B.A., Sainz, R., de la Cuesta., R., Muntz, H.G., Fleischhacker, D, Ek, M., Rice, L.W., Nikrui, N., Tamimi, H.K., Cain, J.M., Greer, B.E. and Fuller, A.F. Jr. (1996) Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis. and resistance to. platinum-based chemotherapy in stage III disease. Gynecol. Oncol. 60:412–417
Ho, E.S., Lai, C.R., Hsieh, Y.T., Chen, J.T., Lin, A.J., Hung, M.H. and Liu, F.S. (2001) p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol. Oncol. 80:189–193
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C. and Thun, M.J. (2006) Cancer statistics 2006. CA Cancer J. Clin. 56:106–130
Kerr, I.D. (2004) Sequence analysis of twin ATP binding cassette proteins involved in translational control., antibiotic resistance., and ribonuclease L inhibition. Biochem. Biophys. Res. Commun. 315:166–173
Lee, K.R., Tavassoli, F.A., Prat, J., Dietel, M., Gersell, D.J., Karseladze, A.I., Hauptmann, S., Rutgers, J., Russell, P., Buckley, C.H., Schwartz, P., Goldgar, D.E., Silva, E.G., Caduff, R.F. and Kubik-Huch, R.A. (2003) Surface epithelial–stromal tumours. In: Tavassoli F.A., Devilee P. (eds) World health organization classification of tumours., pathology and genetics., tumor of the breast. and female genital. organs. IARC, Lyon, pp 117–202
Matias-Guiu, X., Lerma, E. and Prat, J. (1997) Clear cell tumors of the female genital tract. Semin. Diagn. Pathol. 14:233–239
Morgan R.J. Jr., Copeland L., Gershenson D., Locker G., Mclntosh D., Ozols R. and Teng N. NCCN Ovarian Cancer Practice Guildlines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Nov;10(11 Suppl):293–310
Nishimura, S., Tsuda H., Ito K., Jobo T., Yaegashi N., Inoue T., Sudo T., Berkowitz R.S. and Mok S.C. (2007) Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer. and in clear. cell adenocarcinomas of different organs. Hum. Pathol. 38:134–139
Okada S., Tsuda H., Takarabe, T., Yoshikawa, H., Taketani, Y., and Hirohashi, S. (2002) Allelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types. Jpn. J. Cancer. Res. 93:798–806
Osada, R., Horiuchi, A., Kikuchi, N., Yoshida, J., Hayashi, A., Ota, M., Katsuyama, Y., Mellilo, G., and Konishi, I. (2007) Expressions of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms. and allelic loss. of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum. Pathol. 38:1310–1320
Russel, P. (1994) Surface epithelial-stroma tumors of the ovary. In: Kurman R.J. (ed) Blaustein’s pathology of the female genital tract., 4th edn. Springer, New York., pp 705–782
Schaner, M.E., Ross, D.T., Ciaravino, G., Sorlie, T., Troyanskaya, O., Diehn, M., Wang, Y.C., Duran, G.E., Sikic, T.L., Caldeira, S., Skomedal, H., Tu, I.P., Hernandez-Boussard, T., Johnson, S.W., O’Dwyer, P.J., Fero, M.J., Kristensen, G.B., Borresen-Dale, A.L., Hastie, T., Tibshirani, R., van de Rijn, M., Teng, N.N., Longacre, T.A., Botstein, D., Brown, P.O., and Sikic, B.I. (2003) Gene expression patterns in ovarian carcinomas. Mol. Biol. Cell. 14:4376–4386
Schwartz, D.R., Kardia, S.L., Shedden, K.A., Kuick, R., Michailidis, G., Taylor, J.M., Misek, D.E., Wu, R., Zhai, Y., Darrah, D.M., Reed, H., Ellenson, L.H., Giordano, T.J., Fearon, E.R., Hanash, S.M., and Cho, K.R. (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer. Res. 62:4722–4729
Scully, R.E., Young, R.H., and Clement, P.B, (1998) Tumors of the ovary., maldeveloped gonads., fallopian tube., and broad ligament., 3rd edn. Armed Forces Institute of Pathology., Washington, DC
Serov, S.F., and Scully, R.E. (1973) Histological typing of ovarian tumours. In International histological classification of tumours; no. 9. World Health Organization., Geneva
Suehiro, Y., Sakamoto, M., Umayahara, K., Iwabuchi, H., Sakamoto, H., Tanaka, N., Takeshima, N., Yamauchi, K., Hasumi, K., Akiya, T., Sakunaga, H., Muroya, T., Numa, F., Kato, H., Tenjin, Y., and Sugishita, T. (2000) Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas. Oncology 59:50–56
Tsuchiya, A., Sakamoto, M., Yasuda, J., Chuma, M., Ohta, T., Ohki, M., Yasugi, T., Taketani, Y., and Hirohashi, S. (2003) Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker. and a possible. molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol. 163:2503–2512
Tsuda, H., Birrer, M.J., Ito, Y.M., Ohashi, Y., Lin, M., Lee, C., Wong, W.H., Rao, P.H., Lau, C.C., Berkowitz, R.S., Wong, K.K., and Mok, S.C. (2004) Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer. Genet. Cytogenet. 155:97–107
Vazquez de Aldana, C.R., Marton, M.J., and Hinnebusch, A.G. (1995) GCN20, a novel ATP binding cassette protein., and GCN1 reside in a complex that mediates activation of the eIF-2 alpha kinase GCN2 in amino acid-starved cells. Embo. J. 14:3184–3199
Willner, J., Wurz, K., Allison, K.H., Galic, V., Garcia, R.L., Goff, B.A., and Swisher, E.M. (2007) Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum. Pathol. 38:607–613
Yagoda, A. (1990) Phase II cytotoxic chemotherapy trials in renal cell carcinoma: 1983–1988. Prog. Clin. Biol. Res. 350:227–241
Yasui, K., Mihara, S., Zhao, C., Okamoto, H., Saito-Ohara, F., Tomida, A., Funato, T., Yokomizo, A., Naito, S., Imoto, I., Tsuruo, T., and Inazawa, J. (2004) Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer. Res. 64:1403–1410
Zorn, K.K., Bonome, T., Gangi, L., Chandramouli, G.V., Awtrey, C.S., Gardner, G.J., Barrett, J.C., Boyd, J., and Birrer, M.J. (2005) Gene expression profiles of serous., endometrioid, and clear cell subtypes of ovarian. and endometrial cancer. Clin. Cancer. Res. 11:6422–6430
Acknowledgment
This study was supported in part by a grant from Osaka City General Hospital, Osaka Japan, and R33 CA103595 from National Institute of Health, Department of Health and Human Services, Bethesda, MD.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Mok, S.C., Stanley, M.P., Tsuda, H., Birrer, M.J. (2010). Identification of Biomarkers for Clear Cell Ovarian Adenocarcinoma. In: Hayat, M. (eds) Methods of Cancer Diagnosis, Therapy, and Prognosis. Methods of Cancer Diagnosis, Therapy and Prognosis, vol 6. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2918-8_1
Download citation
DOI: https://doi.org/10.1007/978-90-481-2918-8_1
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-2917-1
Online ISBN: 978-90-481-2918-8
eBook Packages: MedicineMedicine (R0)